Watch expert talks, interviews, and insights on Dr. Channel — your video hub for GPCR science, innovation, and community stories. Dr. Channel -Under Construction-

Explore the world of GPCRs with Dr. GPCR Podcast! Join industry leaders as they share insights, stories, and groundbreaking discoveries, enriching our understanding of GPCRs. Delve into the science behind these vital components shaping our collective knowledge. Welcome to the Dr. GPCR Podcast - The Voice of the Community Conversations with the world’s leading GPCR scientists. Exploring discoveries, careers, and ideas shaping human health. In each episode, we sit down with leading experts to explore their career journeys, groundbreaking discoveries, and the impact of their research on our shared understanding of GPCR biology. Launched at the height of the pandemic, the Dr. GPCR Podcast was created with three goals: Share discoveries – Highlight the latest advances in the GPCR field. Amplify voices – Provide scientists a platform to showcase their work. Inspire the future – Motivate the next generation to pursue GPCR research. At its core, Dr. GPCR’s mission is simple yet ambitious: to bring the GPCR community together - across borders and disciplines - to connect, exchange, and collaborate in order to improve human health through a deeper understanding of GPCR biology. Latest Podcast Episodes More podcast episodes Dr. GPCR Podcast Audience Survey We are currently planning our next season and need your help. This short survey will help us understand your needs to bring you exciting and informative content. We also know that you are busy, which is why we designed this short survey that should take you 5 minutes. Fill out this form Be our Guest In each episode, we chat with an expert about their career trajectory, discoveries, and how their research contributed to the shared pool of knowledge about GPCR biology. We’d love to have you on our podcast. To be a guest, fill out the form below, and we’ll be in touch in 48 hours. Fill out this form What others are saying about this podcast "You made it a very comfortable and engaging experience, and it felt like we were chatting over coffee — Yamina thoughtfully guided our chat throughout." Anita Nivedha I think it's really well done. I'm genuinely interested to see how it evolves and grows over time, as I feel it has the potential to develop into something even more impactful. Anonymous This came at just the most perfect time. I hadn't heard a scientific talk outside my lab since February and was starved to hear someone else talk passionately about GPCRs. I've listened to the episodes multiple times and it's just like being at a conference getting new ideas. I just couldn't be happier y'all created this podcast. Anonymous Great initiative, thanks. Carrier paths, choosing research topics, switching fields, late start, failures and successes. Anonymous I enjoy the breadth of questioning that goes beyond just the science, and reveals a bit about the scientists as individuals/mentors/people. Anonymous Really enjoyable science podcast! Dr. Yamina Berchiche interviews leading GPCR scientists on this vibrant, entertaining podcast. I really appreciate the way the podcast educates and mentors, particularly towards junior scientists but also to the community as a wholen Yamina is a great interviewer, getting insight and personal history from her guests. Am very grateful for Dr GPCR livening up the week in these difficult times! Sam @Pharmamechanic Listen and subscribe where you get your podcasts

<< Back to podcast list Strategic Partner(s) Julia Gardner About Julia Gardner Julia is a senior undergraduate student at Duke University, where she studies chemistry and Chinese. Julia has been working as a researcher in Duke's Rajagopal Lab since her first year as an undergraduate. In the Rajagopal Lab, Julia studies the mechanisms of 'biased signaling' at GPCRs, with a specific focus on the chemokine receptor CXCR3. She recently led a project that demonstrated the GPCR kinases (GRKs) can translocate to endosomes, and that the subcellular localization of the GRKs affects a GPCR's biased signaling profile. Last summer, Julia worked at as the first-ever summer intern at Septerna, the GPCR-based biotechnology company founded by Duke Nobel laureate Dr. Robert Lefkowitz. In the fall, Julia will begin her MD/PhD training. Julia Gardner on the web Rajagopal Lab Google Scholar ResearchGate LinkedIn Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Livingston on allosteric opioid modulators, receptor internalization, and navigating the transition from academic GPCR research to biotech. << Back to podcast list Strategic Partner(s) Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane Opioid receptors belong to a class of GPCRs where the pharmacology extends well beyond what equilibrium binding data can show. The first allosteric modulators of opioid receptors were discovered through an academic-industry collaboration and immediately raised a foundational question: without competing for the orthosteric site, how do these compounds actually work? Livingston's PhD research at the University of Michigan addressed this systematically - mapping selectivity, mechanism, and the long-term consequences of modulator exposure on receptor desensitization and tolerance acquisition. Her postdoc in von Zastrow's lab at UCSF introduced a different framework entirely. Rather than measuring endpoint states, she learned to watch receptors move, internalize, and continue signaling from inside the cell - a finding that challenged the membrane-centric assumption underlying much of classical receptor pharmacology. The conversation traces the scientific and personal logic behind each transition: from chemistry to pharmacology, from membrane to endosome, from bench to product development. For Livingston, GPCRs were never purely academic - her entry into the field began with a forensic toxicologist father who tested crime scene samples for controlled substances, and a question about why molecules change who we are. About the Guest Livingston completed her PhD in pharmacology at the University of Michigan, where she investigated the first allosteric modulators of opioid receptors under Traynor, characterizing their selectivity, binding mechanisms, and effects on acute and chronic receptor signaling. She trained as a postdoctoral fellow in von Zastrow's lab at UCSF, where she worked on beta-2 adrenergic receptor internalization using live-cell imaging approaches that track receptor dynamics in real time. She now works at Gator Bio, where she transitioned from Field Application Scientist - serving as a technical liaison between GPCR researchers and analytical instrumentation - to Product Manager, translating customer research needs into commercial tools. Scientific Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity, and therapeutic rationale Receptor internalization and post-endocytic signaling as a paradigm shift in GPCR pharmacology Assay design as an epistemic constraint on pharmacological interpretation Equilibrium vs. dynamic frameworks for studying receptor biology The Field Application Scientist as a career model for GPCR-trained scientists The structural complementarity of academic and industry research in drug discovery Key Insights from the Conversation 1. Allosteric opioid modulators bypass the orthosteric site entirely Rather than competing with morphine or endogenous opioids at the binding pocket, allosteric modulators act at a distinct site on the receptor. Livingston's PhD project was among the first to characterize how these compounds operate - mapping whether activity is receptor-dependent, whether they shift affinity or efficacy, and whether effects persist through desensitization and tolerance. The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering the signaling profiles responsible for side effects. 2. Internalized receptors don't stop working The membrane-centric view of receptor pharmacology assumes signaling ends when a receptor is endocytosed. Von Zastrow's lab challenged this directly, demonstrating that GPCRs continue to generate signals after they leave the cell surface. For Livingston, encountering this finding after a PhD grounded in equilibrium binding required a genuine conceptual reset - the receptor she had been mapping was not anchored to the membrane in the way her training had assumed. 3. An assay measures a specific thing - not the biology you assume it measures One of Livingston's most consistently held principles: understanding exactly what your assay is measuring is not optional. A readout that captures a downstream marker, a surrogate signal, or a population average can yield clean data while systematically pointing in the wrong direction. Misinterpreting assay specificity is, in her view, one of the most consequential and underacknowledged sources of error in pharmacological research. 4. Live-cell imaging makes the dynamic pharmacology of GPCRs visible Where equilibrium assays capture endpoint states, live-cell microscopy reveals what happens between them. During her postdoc, Livingston transitioned from pulling numbers off instruments to watching receptors traffic, cluster, and internalize in real time. She describes the shift as both technically disorienting and visually striking - a different relationship to data than any endpoint assay can produce. 5. Academia and industry are structurally complementary - not competing versions of the same thing Academia can sustain a 15-year investigation of a single receptor question. Industry can screen tens of millions of compounds in the time it takes to write a grant. Livingston argues these structural constraints make the two sectors dependent on each other - and notes that her PhD emerged directly from an academic-industry collaboration that would not have produced the allosteric modulators without both sides present. 6. The Field Application Scientist role is one of the least-known best fits for GPCR-trained scientists The FAS role combines technical depth, customer-facing science, and teaching - a combination Livingston describes as a natural extension of what she valued most in training. The role is rarely discussed in academic career advising, yet it draws directly on GPCR pharmacology skills: deep assay knowledge, the ability to troubleshoot complex data, and fluency across multiple experimental systems. Episode Timeline Timestamps are AI-generated based on transcript analysis and may not reflect exact chapter breaks in the final audio or video. Use as a navigational guide. 00:00 Introduction and ecosystem announcements 02:15 From inorganic chemistry to GPCR pharmacology 03:17 The origin story - forensic toxicology, mental disorders, and GPCRs 06:58 PhD research: first allosteric modulators of opioid receptors 11:58 Know your assay - and why getting it wrong costs more than data 12:36 Choosing von Zastrow's lab and the internalization paradigm shift 14:17 How to choose a postdoc with no trial period 19:07 Beta-2 adrenergic receptors and live-cell imaging at UCSF 22:02 The moment academia stopped making sense 30:54 From Field Application Scientist to Product Manager 38:58 What both roles look like day-to-day 39:28 Three steps for PhDs and postdocs considering industry Selected Quotes "Instead of directly targeting the receptor like morphine or buprenorphine, we target allosterically. We enhance your endogenous tone, we cause pain relief, maybe we mitigate some of these side effects." "To go to Mark's lab where everything is dynamic, everything is moving - this is a live cell where pieces are internalizing, moving - and then to flip it on its head again and say the receptor at the surface might not be the center of the world." "You have to know what your assay is actually measuring. Because you can get this data and you interpret it one way, but if you don't know the nuances, the very intricacies about your assay - you don't actually know what the specificity of the thing you're measuring is - then you can interpret it in a really wrong way." "In industry, you can't spend 15 years trying to solve one problem. There's no way. But in academia, you also can't screen 30 million cell lines in an afternoon. They're completely complementary." About Dr. Kathryn E Livingston Dr. Kathryn E Livingston is currently a Product Manager at Gator Bio , a biotechnology company providing solutions to researchers studying protein-protein interactions. Kathryn obtained her BS in Chemistry from Carnegie Mellon University and went on to receive a Ph.D. in Pharmacology at the University of Michigan. Working under the supervision of Dr. John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid receptors. Research into their mechanism of action in purified systems formed the base of her thesis work. Following this, Kathryn did a post-doctoral fellowship at UCSF in the laboratory of Dr. Mark von Zastrow . There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity in intact cellular systems. Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation, novel methods, or novel communication. Dr. Kathryn E Livingston on the web LinkedIn ResearchGate Pubmed Google Scholar Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Tanishka S. Saraf About Tanishka S. Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes for Fragile X Syndrome. During my PhD, I learnt radioligand binding assays, behavioral assays, autoradiography, stereotaxic surgeries, electroencephalography, immunohistochemistry, mouse colony management and breeding. I would like to keep working in the central nervous system disorders realm to understand the neurobiology of neuropsychiatric disorders and to develop safe and effective treatments. " Tanishka S. Saraf on the web FRAXA Research Foundation Google Scholar ResearchGate LinkedIn Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. John Janetzko About Dr. John Janetzko "I received my Honors BSc in Chemistry from the University of Toronto in 2011, with a focus on synthetic organic and inorganic chemistry. Following this, I pursued graduate studies in Chemistry at Harvard University. At Harvard, I worked in the labs of Drs. Daniel Kahne and Suzanne Walker studying the structure and function of the essential human enzyme, O-GlcNAc transferase (OGT). My Ph.D. work focused on understanding the mechanism of an enigmatic moonlighting function of OGT that had been described only a year earlier. Over the course of my graduate work, I gained experience with structural mass spectrometry and protein crystallography, which shaped my interest in understanding how protein dynamics are linked to function. To further develop these ideas, I joined the lab of Dr. Brian Kobilka at Stanford University at the end of 2017 for postdoctoral work. There, I’ve been working towards understanding the molecular basis of G protein-coupled receptor desensitization and trafficking. My postdoc work has made use of several techniques including various mass spectrometry approaches, single particle cryo-EM and single-molecule fluorescence spectroscopy. In July 2024 I will join the University of Colorado, Anschutz Medical Campus, as an Assistant Professor in the Department of Biochemistry and Molecular Genetics. Besides research, I am passionate about teaching, science communication and making research more inclusive and welcoming. Outside of the lab, I am an avid bike racer, an occasional cycling coach, and I enjoy spending time with my wife, son, and Bernedoodle." Dr. John Janetzko on the web Stanford University Stanford Medicine Google Scholar Personal Website ResearchGate LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap In their conversation, Yamina and John discussed crafting social media posts for John's scientific content. They also shared their respective backgrounds and future plans, with John planning to start his own lab at the University of Colorado School of Medicine. John shared his journey into science, from his interest in creative fields to his involvement in the Chemistry Olympiad and subsequent academic pursuits. The conversation also touched on the challenges of applying for academic positions in the US, the importance of adaptability in one's career, and the potential benefits of networking and mentorship. Next steps • Yamina will share ideas on supporting John's new academic position after the recording stops. • John will prioritize getting feedback from people outside his lab to structure his job seminars. Summary Social Media Post Crafting for GPCRs Yamina and John discussed crafting social media posts for John's scientific content. Yamina emphasized that the content should be kept in a PG-13 context and be scientifically related to GPCRs. John expressed his comfort in sharing his stories and agreed to follow Yamina's guidelines. They also discussed their respective backgrounds and John's future plans to start his own lab at the University of Colorado School of Medicine. John shared his journey into science and his initial interest in creative fields. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen interest in advanced physics and math curriculum. He participated in various academic competitions, including math, physics, and chemistry contests. John explained that he was drawn to chemistry because it allowed him to build things in his mind and design them. He discovered the National Chemistry Olympiad and was selected to attend a provincial training camp at the University of Toronto. This led to his participation in the National Training Program in Quebec City and his selection to represent Canada at the Chemistry Olympiad in Moscow, Russia. John also mentioned his university application process, which was less stressful than the US system. Yamina shared her own experiences with applying to universities in Canada and the US. John's Chemistry Olympiad and GPCR Journey John shared his experience with the Chemistry Olympiad program, highlighting its rigorousness and advanced content that exceeds typical high school curriculums. He also reflected on his journey from his early involvement in a university chemistry lab to his current interest in graduate school, inspired by the innovative approach of using chemistry to understand and build tools for biology. Yamina sought clarification on John's involvement with GPCRs, but the transcript ended before he could respond. John's Scientific Journey and Lab Collaboration John discussed his scientific journey, starting with a project in Suzanne Walker's lab focusing on the essential mammalian protein O-GlcNAc transferase. He then moved to Dan's lab where he met Suzanne and her project. Towards the end of his PhD, John became interested in understanding how proteins operate as large macromolecular machines and decided to work on memory proteins. He chose Brian's lab due to his interest in studying conformational changes. John shared his experience of reaching out to and securing a position in Brian's lab. He detailed his initial email contact, the subsequent Skype meeting, and the in-person visit that led to his acceptance of the position. John also discussed the potential complications that arose when his then-girlfriend, now wife, was applying for residencies. Ultimately, John did join the lab after his girlfriend successfully matched at Stanford. John explained the collaborative culture in Brian's lab, where individuals are encouraged to pursue projects aligned with their interests. He shared his experience working on a project involving receptor kinases and collaborating with other postdocs in the lab to develop assays and improve the biochemistry of certain targets. The conversation emphasized the importance of diverse backgrounds and skill sets in tackling complex challenges and finding solutions. Academia vs. Industry: Career Progression Discussion Yamina and John had a detailed discussion about the prospects of staying in academia versus transitioning to biotech or industry. John shared his thoughts about the great science happening in other sectors and how the decision largely depended on the opportunities presented. Yamina agreed and sought advice from John on career progression in academia. John suggested building milestones and landmarks into a postdoc, such as applying for funding opportunities, and getting diverse feedback to effectively present work. The conversation ended with Yamina asking when a postdoc should start considering their next steps in their career. Academic Position Applications and Transition Preparation John and Yamina discussed the extensive process of applying for academic positions in the US. John suggested starting preparations a year to two years ahead due to the time needed to develop ideas, write proposals, and get feedback. They also highlighted the need for mentorship and networking in finding job opportunities. Yamina questioned whether universities adequately prepare postdocs for the transition to industry or academia, suggesting a detailed manual or guide might be helpful. Both agreed on the importance of adaptability, as unexpected situations like the Covid-19 pandemic can affect the job searching process. John shared his experiences, stating that he submitted approximately 35 to 40 applications and that the interview process is time-consuming. Career Choices and Support in Academia John shared his positive experiences from job interviews and forming friendships with colleagues at various institutions. He also discussed the challenges of choosing between job offers, including considering his wife's career, her family's location in Denver, and other factors like monetary package and colleagues. John emphasized that negotiating salary is often not possible due to strict regulations. Yamina suggested having round tables to discuss these topics. John then reflected on his career, sharing key moments of realization in his scientific work and his upcoming transition out of his lab. The conversation concluded with both John and Yamina expressing a desire to support the academic community in various ways. Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Terry Kenakin About Dr. Terry Kenakin After obtaining a BSc in chemistry at the University of Alberta Edmonton Canada, Terry received his Ph.D. in Pharmacology from the University of Alberta, Department of Chemistry, Canada. Dr. Kenakin then moved to the UK, where he did a post-doctoral fellowship in University College London with Sir James Black. His next stop took him to Burroughs-Wellcome (BW) in Research Triangle Park (RTP) in North Carolina USA. After 7 years at BW, Dr. Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome , and finally GlaxoSmithKline . Since 2011, Terry works at the Department of Pharmacology at the University of North Carolina School of Medicine Chapel Hill NC. His interests are in receptor pharmacology, allosteric protein function, and drug discovery. Dr. Terry Kenakin on the web LinkedIn UNC Department of Pharmacology Amazon ResearchGate Pubmed . Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Lauren M. Slosky About Dr. Lauren M. Slosky Lauren Slosky is an Assistant Professor in the Department of Pharmacology and a member of the Medical Discovery Team on Addiction, a multidisciplinary initiative within the University of Minnesota’s Medical School to advance research and treatment in the field of drug addiction. Dr. Slosky’s research is focused on understanding how neuropeptide G protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic benefit. Dr. Slosky was awarded a B.S. with honors in Molecular and Cellular Biology and Psychology from The University of Arizona in 2011. She received a Ph.D. in Medical Pharmacology from The University of Arizona in 2015 and completed a postdoctoral fellowship in the laboratory of Dr. Marc G. Caron at Duke University. Dr. Slosky opened her laboratory at the University of Minnesota Medical School in 2021. While a postdoctoral fellow, Dr. Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin receptor 1. These ligands stimulate receptor β-arrestin recruitment without activating canonical G protein signaling. Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects characteristic of balanced receptor activation. Because BAMs engage less well-conserved allosteric sites and exert pathway-specific effects on receptor signaling, they are exciting tools for linking distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics. This work was made possible by the optimization of longitudinal intravenous self-administration paradigms for genetically modified mice. Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab is now working to understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development of safe and effective treatments for stimulant and opioid use disorders. Dr. Slosky’s work has been recognized through several travel and research awards, including the William James Psychology Award, the Hank Yamamura Endowed Fellowship in Pharmacology, an NIH F32 Postdoctoral Fellowship, and an NIH K99/R00 Pathway to Independence Award. In addition to research, Dr. Slosky is passionate about training the next generation of scientists and increasing diversity, equity, and inclusion in science. An advocate for trainees at all levels, she served as Service Chairperson and Interim President of the Duke University Postdoctoral Association. She is currently a faculty trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience, and Life Sciences Summer Undergraduate Research Program and is working to build relationships with key stakeholders through institutional and community service. Dr. Lauren M. Slosky on the web Twitter University of Minnesota Department Page LinkedIn Google Scholar PubMed Research Gate Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Peter Robert Banks About Dr. Peter Robert Banks Peter Banks is currently the Scientific Director at BioTek Instruments , now a part of Agilent . His responsibilities include the management of the company’s applications team and providing scientific guidance to the senior management team on new technology and emerging trends impacting life sciences. Before joining BioTek in 2008, Banks was employed by PerkinElmer for a decade. These roles included management of PerkinElmer’s BioPharma R&D program and Chair of the company’s Scientific Advisory Board. Prior to experiences at PerkinElmer and BioTek, Banks was an Assistant Professor in Analytical Chemistry at Concordia University, Montreal, Canada from 1994 to 1998. Dr. Peter Robert Banks on the web LinkedIn Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Graham Ladds About Dr. Graham Ladds Graham studied Biochemistry at the University of Birmingham before completing a Ph.D. in yeast pheromone signaling at Warwick. He continued to work at Warwick as a post-doc studying pro-hormone convertases before securing a 5-year independent fellowship funded through the NHS. This project enabled him to return to his interest in GPCRs. He progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College. In 2020, he was promoted to a Readership/Professor in Receptor Pharmacology and was elected a Fellow of the British Pharmacological Society. His research group uses a combination of pharmacological investigations and mathematical modeling to study factors that control agonist bias at GPCRs. These investigations have enabled him to foster strong collaborations with the pharmaceutical industry (GSK, Takada, and Firmenich) which have recently been enhanced through him being awarded a Royal Society Industry Fellowship to collaborate with AstraZeneca . Dr. Graham Ladds on the web Twitter ResearchGate LinkedIn Google Scholar PubMed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Inês Pinheiro, Monserrat Avila Zozaya & Yamina Berchiche About Inês Pinheiro PharmD by training and Ph.D. candidate in Hartley's lab at the University of Geneva. As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and immuno-oncology. Inês Pinheiro on the web LinkedIn University of Geneva Twitter Dr. GPCR Ecosystem About Monserrat Avila Zozaya I am a cell biologist interested in studying GPCRs, especially adhesion GPCRs. Motivated by my scientific passion, I recently started a postdoctoral fellowship to study the role of GPCRs in the mechanisms of pain and its comorbidities. Monserrat Avila Zozaya on the web Antony Boucard Lab Dr. GPCR Ecosystem About Yamina Berchiche Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs), that control virtually everything in the body, as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at The Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Dr. Amynah Pradhan on why mu opioids worsen migraine, why delta agonists may relieve it, and how chronic disease states rewrite drug discovery. << Back to podcast list Strategic Partner(s) Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox Chronic migraine sits at a peculiar crossroads in opioid pharmacology: sustained mu opioid receptor activation is a well-documented driver of medication-overuse headache, while preclinical evidence points to delta opioid receptor agonism as a candidate to relieve the same disorder. Dr. Amynah Pradhan's lab at the University of Illinois at Chicago has spent years pulling apart that asymmetry — combining mouse models of chronic migraine, cortical spreading depression, and opioid-induced hyperalgesia with peptidomic screens and conditional genetics to ask where the two receptors diverge anatomically, pharmacologically, and in the chronic disease state. The work sits inside a larger argument Dr. Pradhan returns to often: that organisms in chronic pain are fundamentally different biological systems than naïve ones, and that drug discovery fails when it pretends otherwise. For her, this line of work is also personal — the delta opioid receptor has been her scientific focus for nearly two decades, through failed clinical trials in depression and pain, and migraine may finally be where it finds a clinical home. About the Guest Dr. Amynah Pradhan is Associate Professor of Psychiatry at the University of Illinois at Chicago, where her lab studies opioid receptor biology in the context of headache disorders, chronic pain, and their comorbid emotional states. She trained in pharmacology at McGill University with Paul Clarke and completed postdoctoral work at AstraZeneca, with Brigitte Kieffer in Strasbourg, and with Chris Evans at UCLA. Her research integrates behavioral pharmacology, ligand-directed signaling, and mouse models of migraine, and has become central to the small community of basic pharmacologists working inside the headache field. Scientific Themes of the Conversation The mu/delta asymmetry in migraine — why two receptors in the same family produce opposite clinical outcomes Chronic disease states as fundamentally altered biological systems — and what that means for drug discovery Ligand-directed signaling and receptor trafficking — how internalization shapes tolerance and adverse effects The emotional circuitry of chronic pain — and the kappa opioid / dynorphin link The unfinished GPCR frontier — PACAP, CGRP, and the persistent antibody problem Career mobility through collaboration — how a headache neurologist redirected two decades of work Key Insights from the Conversation The yin-yang that organizes the lab. Mu opioid agonists, in chronic use, exacerbate migraine and drive medication-overuse headache. Delta opioid agonists appear to relieve the same symptoms — pain, negative affect, and aura-related signs in preclinical models. Dr. Pradhan treats the contrast not as a side story but as the organizing question of her work. Chronic states are not scaled-up acute states. One of Dr. Pradhan's recurring arguments is that the organism in a chronic disease state is fundamentally altered, and that drug candidates fail in clinical trials partly because they are validated in naïve animals that do not resemble the patients they will eventually treat. Internalization is a design choice, not a side effect. Earlier work in her career showed that high-internalizing delta agonists drive receptor downregulation and tolerance, while low-internalizing agonists uncouple the receptor from ion channels without losing it. The ideal delta agonist, by her account, would be non-internalizing, brain-penetrant, long-half-life, and directed at forebrain circuits where emotional salience of pain lives. Delta agonists may finally have a disease. After failed trials in depression and pain, Dr. Pradhan argues that migraine — with its emotional comorbidity, its anatomical overlap with delta receptor expression, and its distinctive pain mechanisms — may be the clinical home the compound class has been looking for. The conviction is quiet but deeply held. The antibody problem is keeping a field from basic answers. Her "bugaboo": we still do not know reliably where many GPCRs live — which cell type, which compartment, surface versus intracellular — because antibodies for the family are widely unreliable. For a pharmacologist, the resolution problem sits upstream of every other question. A single collaboration can redirect a career. Her move from pure opioid pharmacology into migraine came from sharing a building with neurologist Andrew Charles at UCLA. She treats this as a generalizable lesson for junior scientists: openness to collaboration is not decorative — it is how fields get rewired. The invisible labor of being the only one in the room. Toward the end of the conversation, Dr. Pradhan turns to the structural weight carried by women and scientists of color in academia — the cumulative load of committee service, mentorship, and representation — and argues that real support requires institutions to account for it, not just request it. Episode Timeline Timestamps were generated using AI for readability. 00:00 Introduction 01:13 From McGill to migraine — a path through four labs 04:19 Why mu worsens migraine and delta relieves it 09:27 What chronic dosing does to the receptor — tolerance, internalization, downregulation 14:17 Designing the delta agonist she wants 17:30 The emotional circuitry of chronic pain — and the kappa link 22:22 CGRP, PACAP, and why GPCR drug discovery is not out of runway 28:54 Biased ligands after the hype cooled 34:08 How you measure migraine in a mouse 40:44 Three aha moments — and why delta agonists may finally have a home 43:28 The hidden cost of being the only one in the room 57:05 What the pandemic did to a mouse colony Selected Quotes "The delta opioid receptor is my baby. I've been working on it for almost 20 years under lots of different contexts." "The organism is fundamentally altered in a chronic disease state. They're not in the same state as they were if they were naïve. Patients didn't come to the doctor to look for drugs because they were feeling fine." "Every person I know who studies G-protein coupled receptors will tell you — the antibodies suck. We're still arguing about where the receptor is. What cell type it's on. Is it on the cell surface? Is it inside the cell? The fact that we can't say that is kind of crazy to me." "Maybe the disease state where delta ligands would really be effective would be in headache disorders — in migraines specifically. Maybe this is where it all comes together." About this episode In this episode of the Dr. GPCR podcast , we meet with Dr. Amynah Pradhan. She is an Associate Professor of Psychiatry at the University of Illinois at Chicago. Amynah did her undergrad research measuring IP3 in airway smooth muscle cells and completed a Ph.D. at McGill University in Canada with Dr. Paul Clarck , where she studied opioid receptors. Her next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models of pain and sensory neuron sensitive-receptor. She then returned to academia and worked on opioids as a postdoctoral trainee with Dr. Brigitte Kieffer , where she studied ligand-directed signaling at the delta-opioid receptor. Her career path-defining moment came from a third postdoctoral experience with Dr. Chris Evans at UCLA. Amynah studied how arrestins regulate ligand-directed signaling at delta-opioid receptors, and it is their collaboration with a headache physician-scientist Dr. Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic target to treat headache. Dr. Amynah Pradhan on the web Lab page LinkedIn Twitter Google Scholar PubMed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Nicolas Gilles About Dr. Nicolas Gilles "Dr. Nicolas Gilles is an expert in the study of animal toxins. He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class. His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations, to in vivo validation. When the pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic development initiates through a dedicated start-up." Dr. Nicolas Gilles on the web Google Scholar LinkedIn Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Discover the incredible benefits of the Dr. GPCR University. ​All these benefits are designed to enhance your research experience and keep you informed about the latest developments in GPCR science.​ 🎓 Dr. GPCR University Your Professional Home in GPCR Science Join the community where GPCR researchers learn, connect, and advance together — with expert-led courses, live masterclasses, and career tools built for you. Which best describes you? Select your situation and we'll show you the best plan. I am a... Free Membership Stay connected with the weekly brief, podcast, and public resources. $0 Forever Join for Free Academic Teams Earn full Premium access for your students by teaching a GPCR course within the University. Free Apply as an Instructor Developing Countries Full Premium access for researchers in developing countries. 90% discount, subject to verification. $24.99/year Check Eligibility 14-Day Trial Experience everything the University offers for 14 days. No commitment beyond the trial. $49 14-Day Trial Start Your 14-Day Trial Premium for Teams Unified access for your whole team. 25% discount, minimum 5 seats. $374.25/year Per person Get Your Team Discount Premium Yearly Gift yourself a Premium Membership with a $500 donation to the Dr. GPCR Ecosystem — a 501(c)(3) nonprofit. Tax-deductible. $500/year Less than $10/week Donate & Join Premium Premium Yearly Full access to expert courses, live masterclasses, career tools, and the GPCR community. Easy to expense — we provide a receipt for reimbursement. $499/year Less than $10/week Join Premium Below👇 Team Access for Discovery Groups Full University Premium + Terry's Pharmacology Corner for your entire discovery team. Built for teams aligning pharmacology across programs — so everyone works from the same expert-led foundation. $2,249.25/year Per person, min 5 seats ( 25% team discount ) Get Team Access Premium + Terry's Pharmacology Corner Get full University & Dr. Terry Kenakin's pharmacology access with monthly AMA's — the complete GPCR learning experience in one membership. $2999/year Per person Get the Bundle 🔥 Upgrade to Premium Premium Yearly $499 $ 499 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Today! 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. 🔒 Grandfather Guarantee, your rate never increases Need access for your whole organization? Find the right plan for your team — from small groups to institution-wide access. Explore Team Options → Why is it Worth It? Common concerns and why Premium delivers exceptional value "It's too expensive." At less than $10 a week, University gives you live access to leading GPCR scientists, 200+ on-demand talks, premium intelligence, a job board, events calendar, and a global community of peers. One insight, one connection, one 'aha' moment — can save months of research time. "I already get what I need from papers." Papers inform. University helps you understand and apply that knowledge — through expert context, structured scientific exchanges, and real interaction with peers from academia and industry. "I'm not sure I'll use it often." Even one Masterclass or one new collaboration can make a difference. Members often find value in ways they didn't expect — from expert feedback to career-changing introductions. That's why we offer a 14-day trial, so you can experience it first. "Will this really help my career?" Yes. Members grow visibility, confidence, and connections that open doors. It’s not just about learning — it’s about being seen, supported, and part of something bigger . Premium Membership Benefits Everything you need to stay at the forefront of GPCR research and advance your career. Expert-Led GPCR Courses 200+ Expert Talks Events & Jobs Board Complete GPCR Coverage Community Tools Career Matchmaker Frequently Asked Questions Premium Pricing University What is Dr. GPCR Premium? Who should join Dr. GPCR Premium? What’s included in the Premium membership? How does Premium differ from the free membership? How much does Premium cost? Is there a monthly payment option? Are the courses self-paced? Can I register my entire team for Premium? Do you offer discounts for students or developing countries? What happens after I join? Ready to Join the Community? Start with a 14-day trial and experience everything the University has to offer. Start Your 14-Day Trial — $50

<< Back to podcast list Strategic Partner(s) Vaithish Velazhahan About Vaithish Velazhahan Vaithish obtained dual bachelor’s degrees with honors in Medical Biochemistry and Microbiology from Kansas State University, USA. His undergraduate thesis work on studying the biochemical mechanisms of flavonoids in cancer using nuclear magnetic resonance spectroscopy (NMR) led to a Barry M. Goldwater Scholarship. He then received a prestigious Gates Cambridge Scholarship to study for a Ph.D. at the MRC Laboratory of Molecular Biology and the University of Cambridge, where he is currently a final year Ph.D. candidate. His Ph.D. work has been focused on understanding the structure and activation of Class D fungal GPCRs. He has developed novel tools and methodologies to study fungal GPCRs which allowed the determination of the first structures of the prototypical fungal GPCR Ste2. This work has led to two first-authored manuscripts published in the journal Nature. Vaithish has been recognized with the MRC LMB's Max Perutz Prize for outstanding Ph.D. work and has been elected a Research Fellow at Gonville and Caius College, which is one of the most prestigious positions at the University of Cambridge. Vaithish Velazhahan on the web Twitter GatesCambridge PubMed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Explore GPCR lipid rafts, bitter taste receptor pharmacology, and data integration in this expert interview with Dr. Keyvan Sedaghat. << Back to podcast list Strategic Partner(s) How Lipid Rafts Organize GPCR Signaling This episode features Dr. Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic landscape of bitter taste receptors, and the importance of data-driven resources. Dr. Sedaghat details the construction of an open-access GPCR-lipid raft database and reviews key findings from his research on D1 receptor desensitization and GRK isoform signaling. Listeners gain insights into how membrane microdomains modulate GPCR activity, the translational impact of taste receptors in cancer and metabolic diseases, and emerging high-throughput methods for functional assay development. The conversation underscores the ongoing need for rigorous experimental validation following computational predictions. For more on advanced topics in GPCR drug discovery and methods, browse additional episodes at Dr. GPCR Premium. Why This Matters How lipid raft microdomains selectively regulate GPCR signaling and internalization Why the localization of Gα subunits impacts antidepressant drug efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic targets beyond sensory biology The moment when open-access GPCR data integration improves both research reproducibility and hypothesis generation How computational approaches and wet-lab validation complement each other in functional assay development Who Should Listen If you face complex GPCR questions at the bench or in translational research, this discussion will resonate. When you’re mapping receptor localization and need to understand the mechanistic role of microdomains If you’re expanding functional assays to capture non-canonical GPCR roles in disease When integrating computational predictions with real-world pharmacological readouts If you see the research value in collaborative, up-to-date GPCR data resources About Keyvan Sedaghat Keyvan Sedaghat began his scientific training with a pharmacy degree in Iran, then completed his graduate education in cellular and molecular medicine with a specialization in pharmacology at the University of Ottawa. There, under Professor Mario Tiberi, he focused on G protein-coupled receptors and D1 receptor regulation—work that sparked his ongoing engagement with receptor signaling and microdomain biology. Dr. Sedaghat has accumulated over two decades of teaching and research in pharmacology, contributing as a professor, senior lecturer, editorial board member, and scientific officer in both pharmaceutical and cosmetic sectors. His current efforts bridge teaching in Toronto and ongoing research, including the development of an online GPCR-lipid raft database and investigation of bitter taste receptors’ roles beyond sensory systems. He remains driven by a commitment to rigorous science, data accessibility, and advancing the mechanistic understanding of GPCR pharmacology. Guest on the Web LinkedIn 7TMR-RAFT database Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Advance your GPCR research career with Dr. GPCR University. Access 20+ on-demand GPCR courses, 200+ expert talks, weekly news, and a global scientist network. Join Premium today. Dr. GPCR University Your professional home in GPCR science. University is your professional home in GPCR science — premium intelligence, live Masterclasses, job listings, events, and a community of scientists who have your back. Everything you need, in one place. See what it feels like — $49 for 14 days Already know this is home? Join University — $499/year 1,400+ GPCR scientists reached 200+ Expert talks available $499 Per year — less than $10/week Live Masterclass In the room with the scientist, not watching from the audience Live scientific exchanges where you engage directly with leading GPCR experts. The question you've been holding — this is where you ask it. Dr. Davide Calebiro | University of Birmingham The spatiotemporal organization of GPCR signalling Receptor Signaling September 10, 2026 Dr. Marsha Pierce | Midewestern University Introduction to GLP-1 pharmacology Translational Pharmacology & Disease Models October 8, 2026 Explore Live Masterclasses → On-demand Masterclass library 200+ expert sessions, available anytime Full recordings of every Masterclass session. Revisit the science at your pace — filter by category, level, or instructor. Explore Masterclasses On Demand → Who it's for? Whether you're just starting out or 20 years in — this is your place University is designed for GPCR scientists at every career stage who want to stay sharp, connected, and supported. 🎓 Early-career researchers Find your footing in the field. Access the experts, the intelligence, and the community that accelerates your growth. 🔬 Discovery scientists Stay at the frontier. Live Masterclasses and Premium Weekly News keep you ahead of the field — not chasing it. 🏆 Senior investigators Your career stage doesn't matter. Your commitment to the science does. Connect, contribute, and stay current. What's inside? The rooms in your professional home University isn't a bundle of features — it's a place where your GPCR professional life is supported. Here's what's waiting for you inside. Live Masterclass Live scientific exchanges with leading GPCR experts. You're in the room with the scientist, asking your question — not watching from the audience. Explore Live Masterclass → Job Listings GPCR-specific job opportunities curated for the community. Your next role is already here — opportunities find you when you're inside the ecosystem. Masterclass On Demand Full recordings of every session, available anytime. Revisit the science at your pace — over 200 expert talks in the library and growing. Explore Masterclass on Demand → GPCR Events A calendar of relevant conferences, meetings, and events in the GPCR field. Your next conference is already here. Premium Weekly News The complete GPCR intelligence — classified publications, industry news, job listings, and events calendar. Know what's coming before it becomes consensus. See Weekly News → Ask the Ecosystem The question you've been sitting on — someone in this ecosystem has the answer. A discussion forum where members share insights and get answers from the community. The comparison A society membership costs more and gives you less Most GPCR scientists belong to at least one scientific society. Here's how that compares to University. Typical Scientific Society $150 – $500+/year A journal subscription A conference discount A newsletter Occasional networking events Dr. GPCR University $499/year — less than $10 a week Live Masterclasses with leading GPCR scientists 200+ on-demand expert sessions Premium Weekly News intelligence GPCR job board and events calendar Community forum & ecosystem access Intelligence Hub dashboard Grandfather guarantee — your rate never increases "The one membership that has your back." $49 for 14 days - Strat Now What others are saying Scientists inside the ecosystem Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere GPCR researcher The content had enough depth to satisfy the hunger for theory while being full of practical knowledge GPCR researcher Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him GPCR researcher The course was very practical and easily translatable to experiments that we could do in our own labs. It was clear that Dr. Hoare is very in touch with the technical and human challenges we encounter in our work GPCR researcher Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field GPCR researcher The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology GPCR researcher Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. GPCR researcher Common questions Thinking it over? Fair enough. Here are the concerns we hear most — and honest answers. "It's too expensive." At less than $10 a week, University gives you live access to leading GPCR scientists, 200+ on-demand talks, premium intelligence, a job board, events calendar, and a global community of peers. One insight, one connection, one 'aha' moment — can save months of research time. "I'm not sure I'll use it often." Even one Masterclass or one new collaboration can make a difference. Members often find value in ways they didn't expect — from expert feedback to career-changing introductions. That's why we offer a 14-day trial, so you can experience it first. "I already get what I need from papers." Papers inform. University helps you understand and apply that knowledge — through expert context, structured scientific exchanges, and real interaction with peers from academia and industry. "Will this really help my career?" Yes. Members grow visibility, confidence, and connections that open doors. It’s not just about learning — it’s about being seen, supported, and part of something bigger . Frequently asked questions What is Dr. GPCR University? How do I register for Dr. GPCR University Masterclasses? Who are the Dr. GPCR University Masterclasses designed for? What topics are covered in the masterclasses? Can I register my team for a Dr. GPCR University Masterclasses? Are the masterclasses on-demand or live? Do I need prior knowledge of GPCRs to join the masterclasses? What kind of certification will I receive upon completing a masterclass? Can I access the course material after completing the course? Move in. Look around. See if it's home. For 14 days, this is what it feels like to have everything in one place — intelligence, learning, community, and opportunities. Your first Masterclass is waiting. See what it feels like Already know this is home? Join University — $499/year Your 14-day trial is $50. If University feels like home, it's $499/year — less than $10 a week. Grandfather guarantee: your rate never increases. No surprise charges.

Discover CRO Bank Packages with Dr. GPCR Ecosystem. List your services and your brand on the world's first GPCR CRO Bank. Reach a targeted scientific audience and showcase your organization in the GPCR community. Be Discoverable When GPCR Teams Are Actively Evaluating Services and Tools The GPCR CRO Bank is designed to help service providers and tool companies get found, evaluated, and contacted — not just recognized. Companies present their services in a structured format so GPCR discovery teams can quickly identify relevant capabilities. Curated for quality Reach 1,400+ GPCR researchers Partner with us Today! Who the GPCR CRO Bank is For? Your structured home within the ecosystem The GPCR CRO Bank is a strong fit for companies that want to: Make their services or products easily discoverable within the GPCR ecosystem Present clear, structured product and service offerings in one trusted location Support inbound inquiries from teams actively evaluating CROs, platforms, or tools Use ecosystem visibility to support commercial conversations and decision-making If your primary goal is brand credibility and long-term recognition across high-traffic ecosystem pages, a Strategic Media Partnership may be a better fit. "Dr. GPCR is the world's largest nonprofit community focused on GPCRs. We are building the world's first CRO Service-focused GPCR bank. As a CRO partner, you'll gain trusted access to an engaged audience of biotech teams and drug discovery innovators — without having to fight for attention." Why Partner with Dr. GPCR? Featured across our nonprofit platform, trusted by thousands As a CRO partner, you'll be featured across our nonprofit platform, trusted by thousands of GPCR scientists and biotech professionals. Reach Qualified Researchers Connect with scientists who are actively looking for tools like yours, without the noise of general platforms. Build Trust Develop content that speaks their language and establishes your credibility in the GPCR research community. Join a Curated Ecosystem Become part of a collaborative, curated ecosystem — not just another name on a crowded vendor list. What You Get as a CRO Partner? Built for discovery and evaluation These channels are used to support discovery and evaluation — helping teams understand what you offer and how to engage with you. Premium Licenses 10 Scientists Premium Accounts and 3 Non-Scientists Premium Accounts for your team. Custom Company Page Permanent company profile on the Dr. GPCR Ecosystem with your logo, branding, mission description, contact links, and key highlights. Featured Podcast Episode Be the guest on a dedicated Dr. GPCR Podcast episode. Feature up to 3 team members. Distributed across podcast platforms and social media. Blog Contributions Contribute to blog posts as a valued partner. Share insights on product launches, scientific discoveries, or customer stories. Product or Service Pages Individual pages for each product or service. Educate researchers and showcase technical value. Provide downloadable resources or use cases. Newsletter Visibility Featured in our highly read weekly newsletter. Tell your story with context, clarity, and purpose. Bonus: mentioned in podcast intros/outros. Social Media Promotion Engaging posts about your organization targeted to GPCR researchers and biotech professionals. Shared on LinkedIn and X (Twitter). Co-Branded Events & Training Collaborate on webinars and virtual training sessions to showcase your expertise and engage directly with the GPCR research community. Previous Partners Join these leading organizations Join these leading organizations in the GPCR research ecosystem. Book Ready to share your CRO company with the GPCR world? Book a 30-minute Strategy Call with Yamina to explore whether your capabilities fit within the GPCR CRO Bank.

<< Back to podcast list Strategic Partner(s) Dr. Rosie Dawaliby About Dr. Rosie Dawaliby "I’m an expert in early-stage drug discovery, targeting membrane proteins, especially GPCR. I have 10 years of experience in the development and management of R&D projects and teams in the field of pharmacology, in prestigious academic laboratories as well as in biopharmaceutical companies in Europe and the United States. I hold a Ph.D. in Life Sciences from the University of Lausanne, Switzerland, Department of Biochemistry (2005-2009), where I started working on membranes and membrane protein biochemistry by studying membrane fusion and autophagy in yeast and mammalian cells. I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure and function during my post-doctoral work (2010-2015). This joint project between prof. Brian Kobilka's lab at Stanford University and the SFMB laboratory at the Université Libre de Bruxelles (ULB) resulted in the first systematic study of phospholipid's effect on GPCR conformation and function. In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases. I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences, and know-how from the different stages of my career. Before founding G.CLIPS biotech in June 2020. And since then, my incredible adventure as CEO of this fast-growing company started and is continuing." Dr. Rosie Dawaliby on the web LinkedIn Dr. GPCR Ecosystem G.CLIPS Biotech on the web Website LinkedIn Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

When his lab closed in 2020, Dr. Paul Insel turned dry-lab science into a reframing of COVID-19 pathobiology as a GPCR signaling imbalance — and a figure in The Economist. << Back to podcast list Strategic Partner(s) Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling In the spring and summer of 2020, pharmacologist Dr. Paul Insel did something unusual for a working lab scientist: he stopped pipetting, and started writing. With his UC San Diego postdoc Krishna Sriram, he reread the literature on ACE inhibitors and angiotensin receptor blockers in the context of severe acute respiratory illness and concluded — against a swell of clinical panic — that the case for their danger in COVID-19 didn't hold up. What came next was a series of papers reframing severe COVID-19 as a disease of signaling imbalance: an overdrive of AT1R activation by angiotensin II, paired with a loss of ACE2-generated angiotensin 1-7. The therapeutic logic that follows is less about attacking the virus and more about rebalancing a GPCR-driven system that the infection has thrown off-axis. A figure from that British Journal of Pharmacology paper was later redrawn by The Economist for a general-audience article on COVID pathobiology — an unexpected crossover for work that began as armchair science during a lockdown walk. This conversation matters to Dr. Insel personally because he is, in his own words, a vulnerable patient — immunosuppressed, older, asthmatic — and what he's describing is not abstract. It's what he would want a physician to understand if he were the one in the hospital bed. About the Guest Dr. Paul Insel is Distinguished Professor of Pharmacology and Medicine at UC San Diego, where he also co-directs the MD-PhD program. His research career has centered on GPCR signaling — with particularly deep work on beta-adrenergic receptors, cyclic AMP regulation, and receptor biology across tissue systems. Beyond the lab, he has been a long-standing contributor to the Goodman & Gilman textbook of pharmacology and is writing its next chapter on angiotensin signaling and angiotensin drugs. He is also involved nationally in MD-PhD program leadership. Scientific Themes of the Conversation The angiotensin imbalance hypothesis of COVID-19 pathobiology — AT1R overdrive versus ACE2/Ang 1-7 insufficiency Drug repurposing as a pandemic strategy — from ACE inhibitors and ARBs to PAR1 and PAR4 antagonists The "gas pedals and brakes" philosophy of cell signaling and pharmacology Dry-lab pharmacology and what becomes possible when wet-lab work stops GPCR density and tissue-specific therapeutic opportunity — type II pneumocytes, beta-2 receptors, and the asthma parallel The ethics of acting on conviction — off-label drug use during a pandemic Key Insights from the Conversation The ACE inhibitor scare was built on a bogus reading of the literature. Early in the pandemic, senior clinicians were stopping their own ACE inhibitors and ARBs based on hypothesis-driven fears of worse outcomes. Dr. Insel and Krishna Sriram went to the primary data and concluded the claim was not supported. The review was accepted at Clinical Pharmacology and Therapeutics within weeks. Severe COVID-19 may be a story of signaling imbalance, not just viral damage. The British Journal of Pharmacology paper reframes pathobiology as an imbalance between AT1R activation and ACE2-generated angiotensin 1-7. If the virus disrupts one arm of this receptor-peptide system, the therapeutic question stops being "what do we add?" and becomes "what do we rebalance?" Biology runs on opposing forces, and good pharmacology learns to see them. Kinases and phosphatases. Cyclases and phosphodiesterases. ACE1 and ACE2. Dr. Insel returns repeatedly to his "gas pedals and brakes" frame — a lens that has quietly shaped how he reads both disease mechanism and drug targets across a long career. The lung's beta-2 story has been sitting in plain sight for fifty years. Type II pneumocytes carry the highest beta-2 receptor density in the body. Long-acting beta-agonists paired with glucocorticoids have been the mainstay of asthma treatment for decades. The connection to acute respiratory distress syndrome — and to the mechanism through which dexamethasone actually works — is, in his reading, underdiscussed rather than speculative. "Don't just do something. Stand there." A clinical mentor's line that became the frame for the lockdown months. Four papers in roughly two months — what Dr. Insel calls armchair science. Not casual, not opinion-writing; dry-lab pharmacology done with the same seriousness as bench work, just with different tools. A figure can travel further than the paper it came from. The schematic from the BJP paper was redrawn by The Economist, with attribution, for a general-audience article on COVID pathobiology. Dr. Insel notes wryly that it's the only paper his family has ever really responded to. The ethics of acting on conviction is its own paper. Midway through writing the angiotensin work, Dr. Insel realized no one had written criteria for how to decide about off-label use of a drug during a pandemic — when mechanism is compelling, safety is reasonable, and trial evidence isn't there yet. He is writing that paper with an ethicist and a law-school colleague. It is exactly the kind of work a pharmacologist does when the lab is closed. Episode Timeline Timestamps were generated using AI for readability. 00:00 Opening and 2020 Summit context 01:45 Dry-lab science — how the work shifted when the wet lab closed 02:37 Rereading the ACE inhibitor scare — and the BJP paper that followed 07:40 Expanding the hypothesis — PAR1, PAR4, and upstream pathobiology 11:00 Gas pedals and brakes — biology's architecture of opposing forces 14:00 Type II pneumocytes, beta-2 density, and the asthma parallel 22:40 The ethics of off-label drug use during a pandemic 25:00 Genetic determinants of severity — ACE1 isoforms and population data 28:40 Vaccine development speed and public trust 33:40 Staying sane — pickleball, walking, and community Selected Quotes "Don't just do something. Stand there. That's sort of what we've been doing. And I think we've made some contributions that are pretty interesting. I really want to do something to help people. That's what this is all about, really." — Dr. Paul Insel "Almost most biological systems are all about gas pedals and brakes. We have kinases and phosphatases. We have cyclases that make cyclic AMP and phosphodiesterases that degrade it. Nature has built in these systems consistently." — Dr. Paul Insel "If you would have told me three months ago that I was going to end up having a figure in The Economist — forget about one of the science journals — in The Economist…" — Dr. Paul Insel "It's still about GPCRs." — Dr. Paul Insel About this episode Dr. Paul Insel is currently a Distinguished Professor of Pharmacology and the University of California San Diego. Paul thinks broadly about science and has been actively publishing papers about his ideas on how COVID symptoms could be treated while we wait for a vaccine, particularly about ACE2 and angiotensin. For the past 30 years, he has been the Director of MD/Ph.D. training program at UCSD and has served as Editor or Senior Editor of numerous scientific journals, including but not limited to the Journal of Clinical Investigation, Molecular Pharmacology, British Journal of Pharmacology, and American Journal of Physiology-Cell Physiology. Dr. Paul Insel on the web Insel Laboratory Institute of Engineering in Medicine UC San Diego UCSD Profiles Google PubMed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Advance your GPCR research with expert-led Masterclasses on pharmacology, efficacy, signaling, and drug discovery. Built for serious scientists. University / Masterclass On Demand Every Masterclass session. Anytime. At your pace. The full recording library of GPCR Masterclass sessions — revisit the science, catch what you missed, and explore topics at the depth they deserve. On-demand recordings are included inDr. GPCR University Try it for 14 days Recording library Explore the Masterclass library Full recordings of every Masterclass session. Filter by category, level, or instructor to find exactly what you need. Filter by Category Filter by Level Filter by Instructor Watch Now Jakob Höppner Subcellular PTH1R Regulation: Lessons from Rare Disease Watch Now Sam Hoare How Signaling Kinetics Shapes GPCR Drug Action Watch Now Kenneth A. Jacobson, Matteo Pavan Structure-Based Design of Modulators of Purinergic GPCRs Watch Now Terry Kenakin Designing with Time: GPCR Ligand Kinetics Watch Now Andrew Tobin How to Build Breakthrough GPCR Programs Watch Now Terry Hebert GPCR Signaling in iPSC-Derived Cardiac Disease Models Watch Now Terry Kenakin Assessing Bias: The Practical Approach Watch Now Terry Kenakin From Body to Benefit: Drug Disposition Watch Now Sudarshan Rajagopal The Spatiotemporal Revolution in GPCR Biology Watch Now Bryan Roth GPCR Molecular Glues: Biased Modulation at the Receptor–Transducer Interface Watch Now Terry Kenakin Unconventional GPCR Ligands Watch Now Terry Kenakin The New Frontier of GPCR Therapeutics 1 2 3 1 ... 1 2 3 ... 3 The scientists Learn from world leaders in GPCR research Every session is led by a recognized expert with decades of experience in GPCR pharmacology and drug discovery. Andrew Tobin University of Glasgow Jakob Höppner Endocrine Unit, Massachusetts General Hospital and Harvard Medical School Marsha Pierce Midwestern University Samuel Hoare Pharmechanics LLC Terry Hébert McGill University Yamina Berchiche Dr. GPCR & Yamina's Corner Bryan Roth UNC Chapel Hill Medical School Kenneth Jacobson NIH Matteo Pavan NIH Sudarshan Rajagopal Duke University School of Medicine Terry Kenakin Terry's Corner How it works? Your library. Your pace. 1 Browse or search Filter by scientific category, instructor, or level. Find the session that matches what you're working on right now. 2 Watch at your pace Full recordings with no time limits. Pause, rewind, revisit. The science is here whenever you need it. 3 Go deeper Join the next live Masterclass to ask your questions directly. The recordings are the foundation — the live sessions are where you go further. Want to be in the room live? Live Masterclass sessions run regularly with interactive Q&A. See what's coming up next. See live sessions → What others are saying Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere GPCR researcher Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field GPCR researcher The content had enough depth to satisfy the hunger for theory while being full of practical knowledge GPCR researcher The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology GPCR researcher Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him GPCR researcher Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. GPCR researcher About the GPCR Masterclass What is a GPCR Masterclass? The GPCR Masterclass is a live scientific discussion with a leading expert in GPCR pharmacology, receptor biology, or drug discovery. Sessions focus on research questions, experimental interpretation, and emerging challenges in GPCR science. Are the sessions live or recorded? Who should join? Can I watch sessions later if I miss the live event? Can I watch sessions later if I miss the live event? How do I fit this in my schedule? What makes the Masterclass different from reading papers or textbooks? What happens during the live discussion? 200+ sessions are waiting for you inside University The full on-demand library, plus live Masterclasses, premium intelligence, jobs, events, and a community of GPCR scientists — all in one place. See what it feels like... Try University for 14 days — $50

<< Back to podcast list Strategic Partner(s) Dr. Pierre Eftekhari About Dr. Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development. have been engaged in GPCR cellular and clinical pharmacology as scientist or PI in neonatal lupus, Cardiomyopathy, hypertension, chagas disease. I have participated and initiated methodologies for development of pharmacologically active anti-GPCR antibodies like agonist, antagonist, inverse agonist or blocker. During my Scholar period I have published or contributed in 38 published scientific work mainly in the field of immunology and pharmacology of GPCR. The majority of my research is concentrated on rhodopsin family with a few works on metabotropic receptor. Since the creation of Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma and biotech clients. The latter mainly in target deconvolution and patient stratification." Dr. Pierre Eftekhari on the web Inoviem Scientific ResearchGate LinkedIn Twitter Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Discover our comprehensive Trademark Policy designed to protect the integrity and uniqueness of Dr. GPCR Ecosystem. Learn more on our website today. Trademark Policy Dr. GPCR, Corp (“Dr. GPCR”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com, DrGPCR.com. If Dr. GPCR approves your request to use any Dr. GPCR trademarks, logos, web pages, screenshots, or other distinctive features ("Dr. GPCR Brand"), you agree to be bound by the following terms and conditions (the "Agreement"). You agree to comply with the Guidelines for Third-Party Use of Dr. GPCR Brand Features. So long as you do so, and provided that Dr. GPCR expressly approves your permission request, Dr. GPCR grants you a non-transferable, non-exclusive, royalty-free, limited license to use the Dr. GPCR Brand Features set forth in your corresponding Permission Request Form for the sole purpose and only for the materials set forth therein. Any use of the Dr. GPCR Brand Features must be accompanied by a notice that clearly indicates that the Dr. GPCR Brand Features are trademarks or distinctive brand features of Dr. GPCR Corp. Dr. GPCR reserves the right in its sole discretion to terminate or modify your permission to display the Dr. GPCR Brand Features and to take action against any use that does not conform to these terms and conditions, infringes any intellectual property or other rights, or violates applicable law. Except as set forth above, nothing herein grants or should be deemed to grant to you any right, title, or interest in or to the Dr. GPCR Brand Features. Your use of the Dr. GPCR Brand Features will inure to the benefit of Dr. GPCR. You agree not to challenge or assist others to challenge the Dr. GPCR Brand Features (except to the extent such restriction is prohibited by applicable law), and you agree not to register or attempt to register any domain names, trademarks, trade names, or other distinctive brand features that are confusingly similar to those of Dr. GPCR. The Dr. GPCR Brand Features are provided "as is" and Dr. GPCR disclaims any warranties either expressed or implied by law regarding the Dr. GPCR Brand Features, including warranties of non-infringement. Furthermore, because you are not being charged for use of the Dr. GPCR Brand Features, in no event shall Dr. GPCR be liable to you for the subject matter of this Agreement under any theory of liability including for any direct, indirect, incidental, special, consequential, punitive, exemplary or other damages arising out of this Agreement or the use of the Dr. GPCR Brand Features. This limitation shall apply even if Dr. GPCR was or should have been aware or advised of the possibility of such damages and notwithstanding any failure of the essential purpose of any limited remedy stated herein. Some states do not allow the exclusion of implied warranties or limitation of liability for incidental or consequential damages, so the above limitations or exclusions may not apply to you. You may not assign your rights or delegate your obligations under this Agreement without Dr. GPCR's prior written consent. This Agreement is not intended to benefit, nor shall it be deemed to give rise to, any rights in any third party. These Terms and Conditions shall be governed by the laws of the State of New York without regard to the principles of conflicts of law. Unless otherwise elected by Dr. GPCR in a particular instance, Customer hereby expressly agrees to submit to the exclusive personal jurisdiction of the federal and state courts of New York County, New York. The parties are independent contractors. Neither party shall be deemed to be an employee, agent, partner, or legal representative of the other for any purpose, and neither shall have any right, power, or authority to create any obligation or responsibility on behalf of the other. The waiver by FindYooour, LLC of a breach of any provision hereof shall not be taken or held to be a waiver of the provision itself. If any provision of this Agreement is held by a court of competent jurisdiction to be contrary to law, such provision shall be changed and interpreted so as to best accomplish the objectives of the original provision to the fullest extent allowed by law and the remaining provisions of this Agreement shall remain in full force and effect. This Agreement, the Guidelines for Third-Party Use of Dr. GPCR Brand Features, and the Permission Request Form constitute the entire agreement between the parties regarding the subject matter of this Agreement. If you’ve found a website that uses a Dr. GPCR trademark inappropriately, we’d like to hear about it. Report inappropriate use of a D. GPCR trademark. Buttons And Badges The Dr. GPCR buttons and badges are publisher integration points that applications, websites, and other services (collectively, "Publishers") can add to websites so that Dr. GPCR users can connect to and share on Dr. GPCR. These include: - Dr. GPCR Badge and Follow button This button is a means for Publishers to enable Dr. GPCR users to quickly follow the Publisher's Business Page directly via a widget on the Publisher's website. After clicking the button, the user indicates to follow that Publisher. - Dr. GPCR Share button The share buttons provide a lightweight way for Publishers to invoke a Dr. GPCR Share dialog and can be implemented using a Dr. GPCR icon. The policies below, as well as the Dr. GPCR Buttons and Badges guidelines, the Dr. GPCR Terms of Service, govern a Publisher's use of the Dr. GPCR buttons. Buttons And Badges Policy Publishers may not attempt to discover the identity of a Dr. GPCR button user unless the user consents to share his or her identity with the Publisher via a Dr. GPCR-approved authorization procedure. This prohibition includes identifying users by correlating Dr. GPCR button reporting data from Dr. GPCR with Publisher data. Publishers may not sell or transmit to others any data about a user related to the user's use of any Dr. GPCR button. For the avoidance of doubt, this prohibition includes, but is not limited to, any use of pixels, cookies, or other methods to recognize users' clicks on a Dr. GPCR button, the data of which is then disclosed, sold, or otherwise shared with other parties. Publishers must disclose clearly any data collection, sharing, and usage that takes place on any site, app, or other property as a consequence of using Dr. GPCR buttons. To comply with this disclosure obligation with respect to Dr. GPCR's use of data, publishers have the option to display a prominent link to How Dr. GPCR uses data when you use our partners’ sites or apps. Publishers may not alter or obfuscate a Dr. GPCR button, and Publishers may not associate a Dr. GPCR button with advertising content, such as putting the Dr. GPCR Button on or adjacent to an ad, or placing ads in shared content, unless authorized to do so by Dr. GPPCR. Publishers also may not place in shared content any text, image, or other content that violates the Dr. GPCR User Content and Conduct Policy. For buttons that may be rendered by the Publisher, such as the Sharing link, the Publisher must use only the official Dr. GPCR-provided icon or a plain text and link combination. In either case, Publishers must not mislead users as to the purpose of the link. Publishers may not direct users to click a Dr. GPCR button for purposes of misleading users. Publishers may not promote prizes, monies, or monetary equivalents in exchange for Dr. GPCR button clicks. For the avoidance of doubt, Publishers may direct users to a Dr. GPCR button to enable content and functionality. When a Publisher directs users to a Dr. GPCR Button, the button action must be related to the Publisher or the Publisher's content. For the Share button, the content or functionality that is enabled for the user must also be accessible to any of the user's social connections who also enable it. FindYooour may analyze Publishers' use of a Dr. GPCR button including to ensure Publishers' compliance with these policies and to facilitate Dr. GPCR development of Dr. GPCR Buttons. By using a Dr. GPCR button, Publishers give Dr. GPCR permission to utilize an automated software program, often called a "web crawler," to retrieve and analyze websites associated with a Dr. GPCR button. If Publishers' sites or services are directed at children under 13 or Publishers have actual knowledge that users of their site or service are children under 13, then Publishers must comply with the US Children's Online Privacy Protection Act when using any Dr. GPCR buttons. Buttons And Badges Guideline These guidelines provide you with the design specification for various Dr. GPCR buttons and badges. You can use these assets on your app (website or mobile app) without pre-approval provided you follow these basic guidelines. Use of Dr. GPCR brands in ways not expressly covered by this document is not allowed without prior written consent from Dr. GPCR. Button use must also be in line with this Button's Policy. Dr. GPCR badge, share and follow button branding guidelines Adding a Dr. GPCR badge to your website, email, or marketing campaign makes it easy for fans to follow you, or join your community. Similarly, the compact. The Share button allows visitors to easily share your content with their circles. We prefer that you use the MagyarBusiness.org badge, Share button, and Follow button in their provided formats. Dr. GPCR icon as a button or badge: In certain situations, you might want to use the Dr. GPCR icon to enable users to share content to Dr. GPCR or to link to your Page so that users can follow you. You can do this so long as the context makes it clear what action will be taken when the user clicks on the icon. In addition, the icon must adhere to the Dr. GPCR icon guidelines below, including color scheme, styling, and so forth. Dr. GPCR Brand Permissions All of our brand features are protected by applicable trademark, copyright and other intellectual property laws. If you would like to use any of our brand features on your website, in an ad, in an article or book, or reproduce them anywhere else, or in any other medium, you'll need to receive permission from Dr. GPCR first. And please note that the user experience with all our products should never be altered. Using the Dr. GPCR logo The Dr. GPCR logo is the most prominent visual representation of our brand, and we want it to be used in the right way. We generally do not approve the use of our logo in third-party marketing materials. This includes online and offline advertising collateral such as: Merchandise featuring the Dr. GPCR logo We cannot grant permission for the use of Dr. GPCR Logo in different marketing materials, such as a new T-shirt design, a toy, software packaging, or other products. Screenshots of Dr. GPCR products You don't need our permission when you want to use an unaltered screenshot of our Website (DrGPCR.com or Ecosystem.DrGPCR.com) or the search results page for instructional or illustrative purposes. This applies to print (book, magazine, journal, newspaper) or digital (webpage, DVD, CD, post) formats. Please see below for exceptions to this rule for some of our other products. Don’t use unaltered screenshots of the Dr. GPCR Websites. When we say "unaltered", we mean no superimposed graphics, photos, or ad copy on the screenshot and no changes to the way our product looks. We also don't give permission for advertisers to use Dr. GPCR pages in connection with advertising products or services (for instance, showing a top ranking on Dr. GPCR search result page). We ask that you put the following tagline beneath any image featuring a Dr. GPCR product screenshot or data: Note: Dr. GPCR and the Dr. GPCR logo are registered trademarks of FindYooour LLC., used with permission. Use of trademarks Our trademarks are valuable assets, and we want to ensure that our users and partners use them correctly. These trademarks include the Logo, Buttons, Badges, Website Design, and other pictures and graphic designs owned and created by Dr. GPCR How to use You may use our trademarks to accurately refer to our products or services, as long as such references are appropriate and consistent with our trademark guidelines. You may use only approved versions of our marks. Please follow all of the general trademarks. The trademark usage guidelines apply even to marks that were previously (but are no longer) used in connection with our products. How not to use You may not use, incorporate, or combine any of our trademarks into a third-party brand name, product name, business name, trade name, or slogan. You may not use any of our marks in a way that suggests you are endorsed by or affiliated with Dr. GPCR or our products. For example, you may not use our marks: In domain names As app icons or featured in an app As the most prominent elements on your website On physical merchandise, promotional materials, business cards or business stationery In product reviews Please do not modify or mimic our marks. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

Need help? Submit a problem! Get detailed information about incidents and find solutions. Join us today! Report an Incident Thank you for taking the time to report any incidents or issues you are experiencing with our site. Your comments will help us improve and refine the Ecosystem. Who is submitting this incident? First Name Last Name Email Details about this incident Please describe your concern Link to the page where you experienced difficulties Please feel free to upload screen shots or short videos of your concern. Upload File Upload supported file (Max 15MB) Submit Thanks for submitting!

Dr. Bryan Roth on the DARPA-funded effort to design a non-psychedelic psychedelic for depression — and why the real bottleneck in GPCR drug discovery is the biology, not the chemistry. << Back to podcast list Strategic Partner(s) Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic Psilocybin is in Phase 3 trials for depression, and the early signal is striking — a single dose followed by months of remission. The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every patient can or should take a psychedelic. This raises one of the most consequential questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic effect from the trip? In this conversation, Dr. Bryan Roth describes the DARPA-funded effort his lab is leading to answer that question through structure-guided drug discovery, biased ligand design, and high-throughput functional assays. The discussion ranges across four decades of receptor pharmacology — from the era when the field debated whether opioid receptors were even proteins, to the cryo-EM-driven structure-function loops that now turn over in three weeks. Dr. Roth is unusually candid about what drug discovery against GPCRs actually requires, why most hypotheses still fail at the indication rather than the chemistry, and why a relative's psychotic break when he was five years old set the trajectory that eventually led him here. About the Guest Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. He earned his MD and biochemistry PhD at St. Louis University and trained in pharmacology at NIH and in molecular biology and psychiatry at Stanford. His lab works on serotonin, dopamine, and opioid receptor structure, function, and drug discovery, with a particular focus on neuropsychiatric disease. He invented DREADD technology, leads the NIH Psychoactive Drug Screening Program, and has contributed to structural and pharmacological characterization of dozens of GPCRs. Scientific Themes of the Conversation Biased agonism at the serotonin 2A receptor and the pursuit of a non-psychedelic psychedelic Structure-guided GPCR drug discovery in the cryo-EM era Why drug discovery bottlenecks are biological, not chemical Polypharmacology for complex neuropsychiatric disease Functional assay design — BRET, Tango, and what each captures The historical evolution of receptor pharmacology, from radioligand binding to atomic-resolution structure Key Insights from the Conversation The bottleneck in GPCR drug discovery is the indication, not the chemistry. Dr. Roth is direct about this: with sufficient medicinal chemistry resources and modern assays, you can make a biased ligand for almost any pathway. What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The hypothesis is what fails. Every GPCR is probably good for something — and we mostly don't know what. This is a quiet conviction Dr. Roth has held for years. It reframes the field's task from finding good targets to understanding the biology well enough to connect targets to indications, a problem he believes will take decades more. A single-target drug may be the wrong goal for complex disease. Clozapine, the most effective antipsychotic, hits at least fifty targets. For schizophrenia and other neuropsychiatric conditions, the genetic landscape may simply be too complex for one-receptor drugs to win. The future, Dr. Roth argues, belongs to designed polypharmacology. The DARPA non-psychedelic psychedelic project is real, early, and moving fast. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to the psychedelic experience. The bet is that biased ligands at the serotonin 2A receptor can separate the two. Six weeks in, structures are turning over and chemistry is iterating. Sometimes a discovery validates itself overnight in ways you didn't sanction. Dr. Roth's lab identified salvinorin A as a kappa opioid receptor agonist. The internet seller who supplied the compound disagreed, took naloxone, smoked salvia to disprove it, and emailed back the next morning conceding the point. A reminder of what scientific certainty sometimes looks like outside the lab. The "you'll never make it" verdict can be wrong, repeatedly. A famous scientist at Stanford and an NIH program officer both told Dr. Roth, in different years, to give up basic science. He didn't. The arc from a lab "about as big as your car" at Case Western to leading a thirty-person GPCR lab at UNC is worth sitting with — particularly for early-career scientists who feel the same verdict closing in. BRET captures the initial event; second messengers can mislead you. For analytical work on biased ligands, Dr. Roth's lab leans heavily on BRET-based G protein and arrestin assays because they're relatively insensitive to receptor reserve and capture coupling close to the receptor. Tango and calcium assays are reserved for screening, where false negatives are the real cost. Episode Timeline 00:00 Introduction 02:03 Witnessing a psychotic break at age five 05:00 The visiting professor's lecture that sealed it: receptors 06:30 When the field debated whether opioid receptors were even proteins 11:31 The "dumb luck" of starting on serotonin receptors at NIH 16:43 Studying functional selectivity for the Navy in 1987 22:50 "You're never going to make it as a basic scientist" 28:13 The lab the size of a car at Case Western 35:26 The DARPA project: a non-psychedelic psychedelic for depression 38:21 "I am not uncertain" — the data Bryan won't talk about yet 47:13 Why BRET captures what second-messenger assays miss 51:01 Why most GPCR drug hypotheses fail — and it isn't the chemistry 55:38 Fifty targets, one drug: clozapine and complex disease 01:03:06 The kappa receptor validated in a human trial overnight 01:06:00 Solving the lab's first GPCR structure 01:08:33 Advice for junior scientists who don't have ten Nature papers Timestamps were generated using AI for readability and may shift slightly relative to the final edited cut. Selected Quotes "Every GPCR is good for something, basically. If we make a drug against any GPCR, it's going to be good for some disorder. We don't know what that is. That's the problem." "The reason that so many things fail is not because a chemist didn't do their work, but because the hypothesis was basically wrong. The idea was, if we make a drug against this target, it will be useful in this disease. And that just may be the wrong hypothesis. It typically is the wrong hypothesis." "I was too stupid to listen to him, basically, is what I tell people." "Find the thing that you're really, really passionate about. Find that. And don't pay so much attention to the outcome. It's the doing that's more important." About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. After receiving his MD and Ph.D. in Biochemistry from St. Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry at Stanford. Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. But, it wasn’t always this way. Bryan got fascinated with receptors after attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he is from. He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project to Create Better Psychiatric Medications LinkedIn Bryan Roth on Twitter Roth Lab on Twitter Google Scholar Pubmed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Learn all about the content guidelines for Dr. GPCR Ecosystem website. Get the information you need to create engaging and impactful content. Content and Conduct Policy Dr. GPCR, Corp, LLC (“Dr. GPCR”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com, DrGPCR.com. We rely heavily on users to report content that may violate our policies. After we are notified of a potential policy violation, we may review the content and take action, including restricting access to the content, removing the content, and limiting or terminating a user’s access to Ecosystem.DrGPCR.com products. Note that we may make exceptions to these policies based on artistic, educational, or documentary considerations or when there are other substantial benefits to the public from not taking action. We respect the freedom of speech. Please note that Ecosystem.DrGPCR.com is specializes in GPCR and related subjects. We occasionally modify these policies, so please check back here for updates. Beyond the guidelines listed below, please note that several products and features may have additional policies and terms; check the provided links for those specific requirements. Responsibility for Your Content You are solely responsible for Your Content, and once published, it may not always be withdrawn. You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy, or reliability, or any disclosure by you of information in Your Content that makes you personally identifiable. You represent that you own or have the necessary permissions to use and authorize your Content as described herein. You may not imply that Your Content is in any way sponsored or endorsed by Ecosystem.DrGPCR.com. You may expose yourself to liability if, for example, Your Content contains material that is false, intentionally misleading, or defamatory; violates any third-party right, including any copyright, trademark, patent, trade secret, moral right, privacy right, right of publicity, or any other intellectual property or proprietary right; contains unlawful material, including illegal hate speech or pornography; exploits or otherwise harms minors, or violates or advocates the violation of any law or regulation. Our Right to Use Your Content You also give Ecosystem.DrGPCR.com (Website) a perpetual, irrevocable, worldwide, royalty-free, and non-exclusive license to reproduce, adapt, modify, translate, publish, publicly perform, publicly display, distribute, store and create derivative works of the basic listing information about your entity that you provide to your Ecosystem.DrGPCR.com Account (such as the entity name, location, phone number, list of interest, business category, hours, services, product descriptions, text, videos, contents, and website) We may use Your Content in several different ways, including publicly displaying it, reformatting it, incorporating it into advertisements and other works, creating derivative works from it, promoting it, distributing it, and allowing others to do the same in connection with their websites and media platforms ("Other Media"). As such, you at this moment irrevocably grant us worldwide, perpetual, non-exclusive, royalty-free, assignable, sub-licensable, transferable rights to use Your Content for any purpose. Please note that you irrevocably grant the users of the Site and any Other Media the right to access Your Content in connection with their use of the Site and any Other Media. Finally, you irrevocably waive and cause to be waived against Ecosystem.DrGPCR.com and its users any claims and assertions of moral rights or attribution with respect to Your Content. By "use" we mean use, copy, publicly perform and display, reproduce, distribute, modify, translate, remove, analyze, commercialize, and prepare derivative works of Your Content. Ownership Between you and Ecosystem.DrGPCR.com, you own Your Content. We own the Ecosystem.DrGPCR.com Content, including but not limited to visual interfaces, interactive features, graphics, design, compilation, including, but not limited to, our compilation of User Content and other Site Content, computer code, products, software, aggregate user review ratings, and all other elements and components of the Site excluding Your Content, User Content and Third Party Content. We also own the copyrights, trademarks, service marks, trade names, and other intellectual and proprietary rights throughout the world ("IP Rights") associated with the Ecosystem.DrGPCR.com Content and the Site, which are protected by copyright, trade dress, patent, trademark laws and all other applicable intellectual and proprietary rights and laws. As such, you may not modify, reproduce, distribute, create derivative works or adaptations of, publicly display or in any way exploit any of the Ecosystem.DrGPCR.com Content in whole or in part except as expressly authorized by us. Except as expressly and unambiguously provided herein, we do not grant you any express or implied rights, and we retain all rights in and to the Site and the Ecosystem.DrGPCR.com Content. Advertising Ecosystem.DrGPCR.com and its licensees may publicly display advertisements and other information adjacent to or included with Your Content. You are not entitled to any compensation for such advertisements. The manner, mode, and extent of such advertising are subject to change without specific notice to you. Content We make some of the Ecosystem.DrGPCR.com Site Content available to third parties. You may access and use these content in order to display on your personal computer, website, or blog ("Your Site"), provided that (i) your use of the Feeds is for personal, non-commercial purposes only, (ii) your display of the Feed Content links back to the relevant pages on Ecosystem.DrGPCR.com Website's websites, and attributes Ecosystem.DrGPCR.com as the source of the Content, (iii) your use or display of the Content does not suggest that Ecosystem.DrGPCR.com promotes or endorses any third party causes, ideas, websites, products or services, including Your Site, (iv) you do not redistribute the Content, and (v) your use of the Content does not overburden Ecosystem.DrGPCR.com Website’s systems. Ecosystem.DrGPCR.com reserves all rights in the Content and may terminate the Content at any time. Other User Content (including any that may have been created by users employed or contracted by the Ecosystem.DrGPCR.com Website) does not necessarily reflect the opinion of Ecosystem.DrGPCR.com. We reserve the right to remove, screen, edit, or reinstate User Content at our sole discretion, for any reason or no reason, and without notice to you, from time to time. For example, we may remove a review if we believe it violates our Content Guidelines. We have no obligation to retain or provide you with copies of Your Content, nor do we guarantee any confidentiality with respect to Your Content. Illegal Activities Do not use our Services to engage in illegal activities or promote dangerous and illegal acts. Malicious and Deceptive Practices Do not transmit viruses, malware, or any other malicious or destructive code. Do not distribute content that harms or interferes with the operation of the networks, servers, or other infrastructure of Ecosystem.DrGPCR.com or others. Do not use our Services for phishing scams. Hate Speech Our products are platforms for free expression. But we don't support content that promotes or condones violence against individuals or groups based on race or ethnic origin, religion, disability, gender, age, nationality, veteran status, or sexual orientation/gender identity, or whose primary purpose is inciting hatred on the basis of these core characteristics. This can be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses the line. Personal and Confidential Information Do not distribute other people’s personal and confidential information, such as credit card numbers, confidential national ID numbers, or account passwords, without their permission. Do not post or distribute images or videos of minors without the necessary consent from their legal representatives. Account Hijacking Do not access another user’s account without their permission. Child Exploitation Do not upload or share content that exploits or abuses children. This includes all child sexual abuse imagery (even cartoon images or videos) and all content that presents children in a sexual manner. We will remove such content and take appropriate action, which may include disabling accounts and reporting to the National Center for Missing & Exploited Children (NCMEC) and law enforcement. Note that this policy may additionally apply to any content uploaded or transmitted through Photos or Videos. If you find any content that you think exploits children in this manner, do not share or comment on such content, even if your intent is to bring it to Ecosystem.DrGPCR.com's attention. Instead, flag the content. If you find content elsewhere on the internet, please contact NCMEC directly. Spam Do not spam, including by sending unwanted promotional or commercial content, or mass solicitations. Do not aggressively follow people or aggressively message people that you do not know. Ranking Manipulation Do not manipulate rankings or relevancy using techniques such as repetitive or misleading keywords or metadata. Sexually Explicit Material Do not distribute sexually explicit or pornographic material. Do not drive traffic to commercial pornography sites. Note that your profile photo cannot include mature or offensive content. For example, do not use a photo that is a close-up of a person’s buttocks or cleavage. Harassment, Bullying, and Threats Do not engage in harassing, bullying, or threatening behavior, and do not incite others to engage in these activities. Anyone using our Services to single someone out for malicious abuse, to threaten someone with serious harm, to sexualize a person in an unwanted way, or to harass in other ways may have the offending content removed or be permanently banned from using the Services. In emergency situations, we may escalate imminent threats of serious harm to law enforcement. Keep in mind that online harassment is also illegal in many places and can have serious offline consequences for both the harasser and the victim. Violence Do not distribute depictions of graphic or gratuitous violence. Impersonation Do not use our Services to mislead or confuse users by pretending to be someone else or pretending to represent an organization you do not represent. Regulated Goods and Services Your content cannot promote regulated goods and services, including but not limited to alcohol, gambling, unapproved supplements, tobacco, fireworks, or weapons. If we receive a complaint that such content violates applicable laws and regulations, we will remove and delete the offending content or account. Contests and Promotions Ecosystem.DrGPCR.com allows contests, sweepstakes, and other promotions ("Promotions") to the extent permitted by law, subject to the following policy requirements and legal terms outlined below. 1. Generating spam or encouraging individuals to engage in spam or abuse is strictly prohibited. Please note that the definition of spam on Ecosystem.DrGPCR.com may develop and change over time, and that Ecosystem.DrGPCR.com reserves the right to determine what qualifies as spam. In order to play a part in helping us fight spam and abuse, we have the following specific requirements for Promotions: 1a. The official rules for your Promotion must include a clear statement that anyone found to have created multiple accounts in order to increase their chances of winning, or anyone who posts entries in excess of an entry limit you have set, will be disqualified from the Promotion. You must set an entry limit for your promotion below a level that is likely to encourage spam. 1b. If you ask participants to use tags and/or hashtags in their Promotion entries, they must be relevant to the kind of content users are posting. For example, do not ask for photos of sunsets with #spaghetti. 2. Promotions should not be used to try to circumvent any applicable terms or policies. 3. Do not run Promotions that offer potential rewards in exchange for sharing content, following a user, mentioning a user (other than the contest creator, sponsor, or an affiliate of the contest creator or sponsor), having other users enter the promotion, or voting in polls. Also, avoid running promotions that encourage users to post unoriginal or repetitive content. 4. Please note that doing a public search (via hashtag or otherwise) may not show every entry or every participant in your Promotion. Accordingly, you should not rely solely on the search feature to view or find all entries or participants in your Promotion. 5. Please note that some Promotion entries may be filtered, hidden, or removed from Ecosystem.DrGPCR.com for spam or quality reasons, or any of our other applicable policies or terms of service. Use of Multiple Accounts Do not create or use multiple accounts to evade our policies or bypass blocks or otherwise subvert restrictions placed on your account. For example, if you’ve been blocked by another user or suspended for abuse, don’t create a replacement account that engages in similar activity. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

Join the Adhesion GPCR Workshop 2024 in Mexico City at CINVESTAV, bringing together researchers to explore the latest in GPCR science. Welcome to the Adhesion GPCR Workshop 2024 , hosted in the vibrant heart of Mexico City at the prestigious venue, CINVESTAV - Centro de Investigación y de Estudios Avanzados del IPN (in English: Center for Research and Advanced Studies of the National Polytechnic Institute). About the venue Cinvestav: Centro de investigación y de Estudios Avanzados del IPN Av. Instituto Politécnico Nacional no 2508 Mexico City, C.P. 07360 Room: Auditorium Arturo Rosenblueth *Have an ID card ready (Passport, Driver's license, etc), as this will be required at the venue entrance Register now to join the exclusive Adhesion GPCR Workshop group and stay updated with all the latest event news. Preliminary Program Layout Date Time Title October 23, 2024 October 24, 2024 October 25, 2024 *Flash Presentations: 10 min *Talks 20 min (15 min+ 5 min questions Everything you need to know about the event Listen to Dr. Antony Boucard and Dr. Yamina Berchiche at the Dr.GPCR Newsletter Meet the Organizers behind the AGPCR24 Antony Boucard Jr, PhD Host and Organizer Cinvestav, Mexico City Yamina Berchiche, PhD Co-organizer Dr. GPCR, Boston Andreína Martín Website & Social Media Coordinator Dr. GPCR, Boston Ivanna Rey Executive Assistant Dr. GPCR, Boston

Discover Media Partner Packages with Dr. GPCR Ecosystem. Amplify your brand, reach a targeted scientific audience, and showcase your organization in the GPCR community. The Yearly Glow Only 12 companies per year are invited to become Yearly Glow partners. This isn't advertising — it's a strategic partnership that puts your brand at the center of the scientific conversations that matter most. 1,400+ GPCR scientists reached 25–50% Newsletter open rate 12 strategic partnerships per year — because quality matters Partner with us Today! Who Media Partnerships Are For? Companies that think in years, not quarters Strategic Media Partnerships are ideal for GPCR-focused companies that want to: Strengthen brand credibility and recognition within the GPCR research community Associate their brand with high-quality science, experts, and long-term ecosystem initiatives Be consistently visible across trusted educational and content platforms Build awareness and trust over time — not chase immediate leads If your primary goal is to drive inbound inquiries or make your services discoverable at the point of need, the GPCR CRO Bank may be a better fit. "Dr. GPCR is the world's largest nonprofit community focused on GPCRs. As a strtegic partner, you'll gain trusted access to an engaged audience of academic researchers, biotech teams, and drug discovery innovators — without having to fight for attention." Why Partner with Dr. GPCR? Featured across our nonprofit platform, trusted by thousands As a media partner, you'll be featured across our nonprofit platform, trusted by thousands of GPCR scientists and biotech professionals. Reach Qualified Researchers Connect with scientists who are actively looking for tools like yours, without the noise of general platforms. Build Trust Develop content that speaks their language and establishes your credibility in the GPCR research community. Join a Curated Ecosystem Become part of a collaborative, curated ecosystem — not just another name on a crowded vendor list. What You Get as Media Partner? Active visibility, not passive placement These touch points are designed to reinforce brand presence and credibility through repeated, trusted exposure — not direct lead generation. Yearly Glow Exclusive Gated Content Premium content assets created in partnership — gated to capture and nurture scientist engagement while contributing genuine value to the community. Strategy Partnership Ongoing strategic collaboration to align visibility initiatives with your goals and the community's needs. Launch Campaigns Strategic campaigns that actively drive scientist awareness and traffic toward your offerings, timed to maximize community attention. Logo Positioning Strategic Partner logos are featured across multiple high-traffic ecosystem pages, creating repeated visual association with trusted GPCR content and resources. Base Package — Included 🎙️ Featured Podcast Episode ✓ Be the guest on a dedicated episode of the Dr. GPCR Podcast ✓ Feature up to 3 team members to share your story ✓ Distributed across podcast platforms and social media ✨ Logo positioning ✓ Strategic Partner logos are featured across multiple high-traffic ecosystem pages, creating repeated visual association with trusted GPCR content and resources. 📣 Social Media Promotion ✓ Engaging posts about your organization ✓ Targeted to GPCR researchers and biotech professionals ✓ Shared on LinkedIn and X (Twitter) 📝 Blog Contributions ✓ Contribute to blog posts on the Dr. GPCR platform as a valued partner ✓ Share insights on product launches, scientific discoveries, or customer stories ✓ Reach a targeted scientific audience with your contributions. 📄 Custom Company Page ✓ Permanent company profile on the Dr. GPCR Ecosystem ✓ Logo, branding, and description of your mission ✓ Contact links and key highlights 📬 Newsletter Visibility ✓ Featured in our highly read weekly newsletter ✓ Tell your story with context, clarity, and purpose ✓ Bonus: Mentioned in podcast intros/outros 👩🔬 Premium Licenses ✓ 10 Scientists Premium Accounts ✓ 3 Non-Scientists Premium Accounts 🎤 Co-Branded Events & Training ✓ Collaborate on webinars and virtual training sessions to showcase your expertise ✓ Host educational events that focus on GPCR research ✓ Engage directly with the GPCR research community through these initiatives 12 per year — a commitment to quality Only 12 Yearly Glow seats are available each year to keep our ecosystem curated, impactful, and community-focused. Every partner deserves dedicated attention, personalized strategy, and genuine integration. This is real selectivity — a reflection of how seriously we take partner quality and community trust. Previous Partners Join these leading organizations Join these leading organizations in the GPCR research ecosystem. Book Book a 30-minute Strategy Call with Yamina Ready to Connect with the GPCR Community? With only 10 spots remaining for 2026... Secure your place in our exclusive media partner program today.

How receptor residence time — not affinity — rescued a CRF drug discovery program, and why a career in GPCR data analysis starts with asking what the math never captured. << Back to podcast list Strategic Partner(s) Sam Hoare: Receptor Residence Time and GPCR Data Analysis For most of GPCR pharmacology's history, affinity was the number that drove decisions. Which ligand binds tightest, ranks highest, earns the most attention in an SAR campaign. But affinity is a snapshot. It tells you how tightly a compound binds at equilibrium — not how long it stays. When Sam Hoare and the CRF receptor team at Neurocrin Biosciences discovered that their lead compound sat on the receptor for seven hours while a failed backup fell off in fifteen minutes, it exposed a variable drug discovery had been systematically ignoring. That discovery became the foundation of a career built on the data most pharmacologists generate but don't analyze. Sam Hoare brings a data analyst's perspective to GPCR pharmacology — one trained in allosteric modulation, sharpened in Class B receptor biology at the NIH, and refined across fifteen years of industrial drug discovery. His current work extends that logic into signaling kinetics: the time dimension in GPCR signaling that labs routinely measure and almost never formally quantify. For Hoare, the unsolved problem isn't the biology — it's the math no one wrote down. About the Guest Sam Hoare is the founder of Pharmechanics , a pharmacology data analysis consultancy. After a PhD on allosteric modulation of dopamine receptors in Philip Strange's UK lab and a postdoc at the National Institutes of Health studying Class B GPCRs, he spent fifteen years at Neurocrin Biosciences working on CRF receptor drug discovery programs that advanced compounds into clinical trials. Hoare now consults for biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics, and pharmacological modeling. His independent research focuses on developing accessible mathematical tools for kinetic analysis of GPCR signaling data, including freely available Prism templates and Excel simulators. Scientific Themes of the Conversation Receptor residence time as a determinant of in vivo drug efficacy — and why affinity alone is insufficient Signaling kinetics: quantifying the time dimension of GPCR pharmacology Allosteric modulation and the mathematical foundations of receptor theory Biased agonism and constitutive activity as practical tools in the drug discovery toolbox The tractability of GPCRs as a pharmacological system — assay accessibility, theory, and the generous culture of the field Scientific consulting: translating deep pharmacological expertise into independent problem-solving practice Key Insights from the Conversation 1. The Off-Rate That Saved a Program Standard binding assays showed identical affinity. But when Beth Fleck measured dissociation rates of the CRF receptor radioligands, the compound that worked in vivo stayed on the receptor for seven hours at room temperature. The failed backup fell off in fifteen minutes. The Neurocrin team had to confront an explanation no assay had been designed to find — and then built new SAR campaigns around it. 2. Affinity Is a Snapshot; Time Is the Story Hoare draws a sharp analogy: running pharmacology dose-response experiments for decades without fitting a sigmoid curve to calculate EC50 would be considered absurd. Yet that is precisely how most labs treat time-course signaling data — collecting it, plotting it, and moving on without extracting a quantitative parameter. His ongoing research exists to close that gap. 3. GPCR Theory Was Built to Be Used One of Hoare's recurring arguments is that GPCRs are unusually tractable — not just as biological targets, but as analytical systems. The underlying pharmacological theory, from operational models of agonism to allosteric binding equations, was designed to be applied by bench scientists. The barrier is not the math itself but the habit of reaching for it. 4. A Mentor Who Worked at the Bench During a difficult stretch of his NIH postdoc, Hoare's supervisor Ted Usdin handed him a defined molecular biology project and spent two months working alongside him at the bench. The intervention was straightforward. The effect on Hoare's confidence — and ultimately his career — was not. He describes it as one of the moments his career most depended on. 5. The Variable Most Drug Programs Miss The CRF residence time story is not unique in Hoare's telling. Across multiple programs — including work on a vesicular transporter where in vitro affinity at pH 7.4 vanished entirely at the physiological vesicle pH of 5.5 — the pattern recurs: assays designed for convenience rather than physiological relevance produce data that can't predict what happens in vivo. The pharmacologist's job is to identify which variable is missing. 6. Emotional Intelligence as a Consultant's Core Skill Hoare was not expecting consulting to teach him about emotional intelligence. What he found was that clients arriving with a data problem are rarely arriving with just a data problem. The ability to serve as a sounding board — to help people relax around their data and see what was obscured by the pressure of having it not make sense — turned out to be as important as the pharmacological expertise he was hired for. 7. Early-Career Researchers Know More Than They Think Hoare makes an argument that surprised him when he first articulated it: a newly minted PhD who has spent six years on a single GPCR target knows things a company working on that receptor genuinely cannot find anywhere else. The practical knowledge of what buffer conditions work, what assay artifacts to expect, what the literature actually shows — that depth of expertise is marketable, and most early-career scientists don't recognize that they have it. Episode Timeline Timestamps are AI-generated from the transcript and may not reflect final edited video timing. 00:00 Sponsor message 00:35 Introducing Sam Hoare: pharmacology data analyst and GPCR consultant 03:19 Origin story — the ATP calculation that first connected math to biology 06:16 PhD with Philip Strange: allosteric modulation of dopamine receptors and the first aha moment 16:53 Why GPCRs? Tractability, accessible theory, and a famously generous field 22:55 NIH postdoc: Class B GPCRs, mentorship, and conversations with Nobel laureates 35:38 Into industry: the CRF receptor team at Neurocrin Biosciences 43:25 The off-rate aha moment: seven hours on the receptor versus fifteen minutes 52:22 Founding PharmaChanics: the decision to leave industry and go independent 01:16:46 Signaling kinetics: the time dimension most pharmacologists skip 01:45:04 Biased agonism and residence time as tools in the drug discovery toolbox 01:52:09 Building a consulting practice: network, marketing, and knowing your worth 02:05:22 Top three aha moments from a career in pharmacological data analysis Selected Quotes "The one that works had a really long residence time on the receptor. We measured it at room temperature and it didn't come off after seven hours. There was just no dissociation. And the one that didn't work in vivo came off in fifteen minutes." "Imagine doing pharmacology dose-response experiments for twenty years without applying the sigmoid curve fit to determine the EC50. To me, that's what we've been doing with time-course signaling data." "He basically gave me a cookie-cutter molecular biology project and worked with me at the bench directly for two months. It completely restored my confidence. I kind of owe a lot of my career to Ted." "My talent really is in data analysis. People would always come to me for that rather than for doing the experiments — and one of the reasons I set up my consultancy was that biology was becoming so technical that it was like I decided to specialize." About Dr. Samuel Hoare Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors, from the University of Kent, United Kingdom. He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class B GPCRs as part of his postdoctoral training. Today, Sam is a pharmacology data analyst and the founder of Pharmechanics LLC , a consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics and the understanding of receptor systems. As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics, particularly GPCR antagonists. Before founding Pharmechanics in 2016, Dr. Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences . He guided the in vitro biology efforts of the company for numerous drug discovery campaigns. Sam is known for demystifying complicated and newly-emerging pharmacology concepts, enabling them to be applied by project teams in optimizing new molecules. I very much enjoyed chatting with Sam about his love for GPCRs, kinetics, and decorticate the complexities of GPCR function to better target receptors. Dr. Samuel Hoare on the web Pharmechanics LLC LinkedIn Pubmed Google Scholar YouTube Dr. GPCR Member ResearchGate Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Jean-Philippe Pin About Dr. Jean-Philippe Pin Jean-Philippe Pin participated in the discovery of metabotropic glutamate receptors. Since then, he has been studying the allosteric modulation and activation mechanism of this family of G protein-coupled receptors using innovative approaches, including biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic agents. His studies led to new concepts in the GPCR field, such as the activation of cell surface receptors by intracellular proteins; the regulation of GPCRs by both negative and positive allosteric modulators, and the asymmetric functioning of GPCR dimers. Dr. Jean-Philippe Pin on the web LinkedIn ResearchGate CNRS Fondation Bettencourt Schueller FRC Neurodon Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>